VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
BNGO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
BNGOBionano Genomics, Inc.
$1.70$20M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
BNGO logo

Bionano Genomics, Inc.

BNGO
NASDAQ · Diagnostics & Research
$1.70
At close - Sep 23, 4:00 PM EDT - USD
Market Cap$20M
P/E-0.4x
52W High$2.23
Volume902.36K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Operational Losses Threaten Future Liquidity Position

Bionano Genomics faces a challenging outlook as its Optical Genome Mapping technology struggles to achieve commercial scale, evidenced by a consistent inability to generate positive operating income. The company's financial health is currently strained by a ra...

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsNeutral
Explore valuation models
MARKET ACTION

BNGO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 91 · Leader

High momentum (Outperforming 91% of market)

04

Trend Check

N/A

Trend data unavailable

Next CatalystConfirmed earnings · Nov 12

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
BNGO+6.92%
S&P 500 (^GSPC)+12.39%
1-Year Return
BNGO+1.19%
S&P 500 (^GSPC)+15.77%
3-Year Return
BNGO-99.05%
S&P 500 (^GSPC)+74.86%
5-Year Return
BNGO-99.95%
S&P 500 (^GSPC)+69.77%

Growth & profitability

Annual revenue & EPS trend
Revenue
$29M-7.4% YoY
Net income
-$26M+76.4% YoY
Free cash flow
-$16M+76.3% YoY
Operating margin
-116.9%+220.9 pts YoY
ROIC (TTM)-49.1%
Avg ROIC 5Y-
ROE (TTM)-66.2%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 10, 2026
-$0.64+4.5%
vs -$0.67
$8M+8.2%
vs $8M
Q2 2026
May 13, 2026
-$0.76+6.2%
vs -$0.81
$7M+1.8%
vs $7M
Q2 2026
Mar 23, 2026
-$0.03+96.3%
vs -$0.81
$8M+0.9%
vs $8M
Q4 2025
Nov 13, 2025
-$1.59+12.2%
vs -$1.81
$7M-6.7%
vs $8M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
GlobeNewsWire·Sep 14, 2026
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia

Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasms Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasms

GlobeNewsWire·Sep 10, 2026
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors (MACs), has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms.

GlobeNewsWire·Sep 8, 2026
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies at University of Rochester Medicine New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies at University of Rochester Medicine

GlobeNewsWire·Aug 24, 2026
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026.

Filtered for Bionano Genomics, Inc.More Headlines
04

Compare before deciding

Benchmark BNGO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Bionano Genomics, Inc. (BNGO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
BNGO logoBNGOBionano Genomics, Inc.Current
$1.70$19.51M-0.35-7.37%-92.59%-66.15%—
PACB logoPACBPacific Biosciences of California, Inc.
$1.41$437.95M-0.773.89%-82.49%-4961.74%—
CDNA logoCDNACareDx, Inc
$54.31$2.81B-135.7813.79%24.23%32.81%—
NTRA logoNTRANatera, Inc.
$390.79$55.97B-257.1035.9%-7.11%-11.73%—
ILMN logoILMNIllumina, Inc.
$255.38$38.64B46.86-0.78%18.36%31.08%—
EXAS logoEXASExact Sciences Corporation
$104.91$20.02B-95.3717.69%-6.4%-8.66%—

Compare BNGO vs Peers

Bionano Genomics, Inc. (BNGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PACB

Most directly comparable listed peer for BNGO.

Scale Benchmark

vs TMO

Larger-name benchmark to compare BNGO against a more recognizable public peer.

Peer Set

Compare Top 5

vs PACB, CDNA, NTRA, ILMN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

BNGO SEC Filings & Documents

Bionano Genomics, Inc. (BNGO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 10, 2026·SEC

Material company update

Jun 24, 2026·SEC

Material company update

Jun 5, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 31, 2025·SEC

FY 2024

Mar 5, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 10, 2026·SEC

FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when BNGO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BNGO Frequently Asked Questions

Bionano Genomics, Inc. (BNGO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Bionano Genomics, Inc.'s revenue?

Bionano Genomics, Inc. (BNGO) reported $30.2M in revenue for fiscal year 2025. This represents a 344% increase from $6.8M in 2016.

How fast is Bionano Genomics, Inc. growing?

Bionano Genomics, Inc. (BNGO) saw revenue decline by 7.4% over the past year.

Is BNGO profitable?

Bionano Genomics, Inc. (BNGO) reported a net loss of $32.2M for fiscal year 2025.

Dividend & Returns
What is BNGO's return on equity?

Bionano Genomics, Inc. (BNGO) has a return on equity (ROE) of -66.2%. Negative ROE indicates the company is unprofitable.

What is Bionano Genomics, Inc.'s free cash flow?

Bionano Genomics, Inc. (BNGO) had negative free cash flow of $20.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in BNGO back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →